1
|
Liang SQ, Du J, Yan H, Zhou QQ, Zhou Y, Yuan ZN, Yan SD, Fu QX, Wang XH, Jia SZ, Peng JC, Zhang YG, Zhan LS. A mouse model for studying the clearance of hepatitis B virus in vivo using a luciferase reporter. PLoS One 2013; 8:e60005. [PMID: 23577080 PMCID: PMC3618179 DOI: 10.1371/journal.pone.0060005] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2012] [Accepted: 02/25/2013] [Indexed: 01/28/2023] Open
Abstract
Hepatitis B virus(HBV) infection remains a global problem, despite the effectiveness of the Hepatitis B vaccine in preventing infection. The resolution of Hepatitis B virus infection has been believed to be attributable to virus-specific immunity. In vivo direct evaluation of anti-HBV immunity in the liver is currently not possible. We have developed a new assay system that detects HBV clearance in the liver after the hydrodynamic transfer of a reporter gene and over-length, linear HBV DNA into hepatocytes, followed by bioluminescence imaging of the reporter gene (Fluc). We employed bioluminescence detection of luciferase expression in HBV-infected hepatocytes to measure the Hepatitis B core antigen (HBcAg)-specific immune responses directed against these infected hepatocytes. Only HBcAg-immunized, but not mock-treated, animals decreased the amounts of luciferase expression, HBsAg and viral DNA from the liver at day 28 after hydrodynamic infection with over-length HBV DNA, indicating that control of luciferase expression correlates with viral clearance from infected hepatocytes.
Collapse
Affiliation(s)
- Sheng-qiang Liang
- Lab of Blood-Borne Viruses, Beijing Institute of Transfusion Medicine, Beijing, China
- Department of Clinical Laboratory, the 175th Hospital of PLA, Affiliated Dong nan Hospital of Xiamen University, Zhang zhou, China
| | - Juan Du
- Lab of Blood-Borne Viruses, Beijing Institute of Transfusion Medicine, Beijing, China
| | - Hu Yan
- Lab of Blood-Borne Viruses, Beijing Institute of Transfusion Medicine, Beijing, China
| | - Qian-qian Zhou
- Lab of Blood-Borne Viruses, Beijing Institute of Transfusion Medicine, Beijing, China
| | - Yong Zhou
- Lab of Blood-Borne Viruses, Beijing Institute of Transfusion Medicine, Beijing, China
| | - Zhen-nan Yuan
- Lab of Blood-Borne Viruses, Beijing Institute of Transfusion Medicine, Beijing, China
| | - Shao-duo Yan
- Lab of Blood-Borne Viruses, Beijing Institute of Transfusion Medicine, Beijing, China
| | - Qiu-xia Fu
- Lab of Blood-Borne Viruses, Beijing Institute of Transfusion Medicine, Beijing, China
| | - Xiao-hui Wang
- Lab of Blood-Borne Viruses, Beijing Institute of Transfusion Medicine, Beijing, China
| | - Shuai-zheng Jia
- Lab of Blood-Borne Viruses, Beijing Institute of Transfusion Medicine, Beijing, China
| | - Jian-chun Peng
- Lab of Blood-Borne Viruses, Beijing Institute of Transfusion Medicine, Beijing, China
| | - Yang-gen Zhang
- Department of Clinical Laboratory, the 175th Hospital of PLA, Affiliated Dong nan Hospital of Xiamen University, Zhang zhou, China
| | - Lin-sheng Zhan
- Lab of Blood-Borne Viruses, Beijing Institute of Transfusion Medicine, Beijing, China
- * E-mail:
| |
Collapse
|
2
|
Ma CL, Wang GB, Gu RG, Wang F. Construction and characterization of calreticulin-HBsAg fusion gene recombinant adenovirus expression vector. World J Gastroenterol 2010; 16:3078-82. [PMID: 20572313 PMCID: PMC2890950 DOI: 10.3748/wjg.v16.i24.3078] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To generate recombinant adenoviral vector containing calreticulin (CRT)-hepatitis B surface antigen (HBsAg) fusion gene for developing a safe, effective and HBsAg-specific therapeutic vaccine.
METHODS: CRT and HBsAg gene were fused using polymerase chain reaction (PCR), endonuclease digestion and ligation methods. The fusion gene was cloned into pENTR/D-TOPO transfer vector after the base pairs of DNA (CACC) sequence was added to the 5′ end. Adenoviral expression vector containing CRT-HBsAg fusion gene was constructed by homologous recombinantion. The human embryo kidney (HEK) 293A cells were transfected with linearized DNA plasmid of the recombinant adenoviral vector to package and amplify recombinant adenovirus. The recombinant adenovirus titer was characterized using the end-dilution assay. The expression of the CRT/HBsAg fusion protein in Ad-CRT/HBsAg infected 293A cells was detected by Western blotting.
RESULTS: The CRT-HBsAg fusion gene was characterized by PCR and sequencing and its length and sequence were confirmed to be accurate. The CRT-HBsAg fusion gene recombinant pENTR/D-TOPO transfer vector was constructed. The recombinant adenoviral vector, Ad-CRT/HBsAg, was generated successfully. The titer of Ad-CRT/HBsAg was characterized as 3.9 × 1011 pfu/mL. The CRT-HBsAg fusion protein was expressed by HEK 293A cells correctly.
CONCLUSION: CRT/HBsAg fusion gene recombinant replication-defective adenovirus expression vector is constructed successfully and this study has provided an experimental basis for further studies of Hepatitis B virus gene therapy.
Collapse
|
3
|
Zhou Q, Wang F, Yang F, Wang Y, Zhang X, Sun S. Augmented humoral and cellular immune response of hepatitis B virus DNA vaccine by micro-needle vaccination using Flt3L as an adjuvant. Vaccine 2010; 28:1357-62. [DOI: 10.1016/j.vaccine.2009.11.006] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2009] [Revised: 10/20/2009] [Accepted: 11/05/2009] [Indexed: 11/26/2022]
|
4
|
Wang Y, Li DA, He Y, Wang F, Guo YJ, Yang F, Zhou Q, Sun SH. Proteomic analysis of augmented immune responses in mouse by prime-and-boost immunization strategy with DNA vaccine coding HBsAg and rHBsAg protein. Vaccine 2007; 25:8146-53. [DOI: 10.1016/j.vaccine.2007.09.037] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2006] [Revised: 09/07/2007] [Accepted: 09/15/2007] [Indexed: 11/16/2022]
|
5
|
Jiang W, Jiang P, Li Y, Tang J, Wang X, Ma S. Recombinant adenovirus expressing GP5 and M fusion proteins of porcine reproductive and respiratory syndrome virus induce both humoral and cell-mediated immune responses in mice. Vet Immunol Immunopathol 2006; 113:169-80. [PMID: 16777236 DOI: 10.1016/j.vetimm.2006.05.001] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2006] [Accepted: 05/01/2006] [Indexed: 11/30/2022]
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) is one of the most important contagious agents of swine in the world. PRRSV infection poses a challenge to current vaccination strategies. In this study, three replication-defective adenovirus recombinants were developed as potential vaccine against PRRSV in a mouse model. Three groups of BALB/c mice (24 mice per group) were inoculated subcutaneously twice at 2-week intervals with the recombinants expressing PRRSV GP5 (rAd-GP5), M (rAd-M), and M-GP5 fusion protein (rAd-M-GP5). Two additional groups were injected with wild-type adenovirus (wtAd) or PBS as control. The results showed that the mice inoculated with recombinant adenoviruses developed PRRSV-specific antibodies, cellular immune response by 2 weeks post second inoculation. However, only mice immunized with recombinant adenovirus rAd-M-GP5 developed significantly higher titers of neutralizing antibodies to PRRSV and produced stronger lymphocyte proliferation responses compared to mice immunized with rAd-M or rAd-GP5 alone. It was also found that mice immunized with rAd-M-GP5 were primed for significant higher levels of anti-PRRSV CTL responses than mice immunized with rAd-M. Mice receiving rAd-GP5 also mounted PRRSV-specific response, but levels were lower. It suggested that the recombinant adenovirus expressing M-GP5 fusion protein might be an attractive candidate vaccine to be tested for preventing PRRSV infection.
Collapse
Affiliation(s)
- Wenming Jiang
- Key Laboratory of Animal Diseases Diagnostic and Immunology, College of Veterinary Medicine, Nanjing Agricultural University, Ministry of Agriculture, Nanjing 210095, China
| | | | | | | | | | | |
Collapse
|
6
|
Youm JW, Won YS, Jeon JH, Ryu CJ, Choi YK, Kim HC, Kim BD, Joung H, Kim HS. Oral immunogenicity of potato-derived HBsAg middle protein in BALB/c mice. Vaccine 2006; 25:577-84. [PMID: 16945456 DOI: 10.1016/j.vaccine.2006.05.131] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2005] [Revised: 05/23/2006] [Accepted: 05/24/2006] [Indexed: 11/29/2022]
Abstract
The antibodies to preS2 synthetic peptides have been probed to neutralize hepatitis B virus (HBV), and also the addition of preS2 sequence could enhance the antibody response compared with a conventional vaccine in the non- and low responders. Previously, we generated transgenic potatoes expressing middle protein, which contains additional 55 amino acid preS2 region at the N-terminus of the S protein, of HBV to determine the feasibility of developing a plant-delivered HBV vaccine. In this study, we monitored the immune response after induction of immunoglobulin by boosting and assessed the efficacy of the mucosal immune response with regard to generate IgA antibodies. The HBsAg middle protein expressed in our transgenic potatoes was well immunized at low antigenic quantities in mice and the induced anti-S or anti-preS2 antibodies were sustained for the whole period without decrease. Orally delivery of plant-derived HBsAg middle protein to mice resulted in fecal anti-S or anti-preS2 as well as serum IgG. In addition, we used antibodies induced from the immunized mice with the potato-derived rHBsAg in competition assay as competitors to confirm the binding ability of preS2 antibodies to surface antigen of hepatitis virus. Anti-preS2 antibodies induced from immunized mice with transgenic potatoes effectively competed with anti-preS2 murine antibody H8 as expected. From these results, the inclusion of preS2 antigen to HBV plant vaccine may provide additional protective immunity in the HBV prevention.
Collapse
Affiliation(s)
- Jung-Won Youm
- Plant Genomics Research Center, KRIBB, 52 Oun-Dong, Yusung-Gu, Daejon 305-333, Republic of Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Xiao-wen H, Shu-han S, Zhen-lin H, Jun L, Lei J, Feng-juan Z, Ya-nan Z, Ying-jun G. Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting. Vaccine 2005; 23:1649-56. [PMID: 15705468 DOI: 10.1016/j.vaccine.2004.10.013] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2004] [Accepted: 10/11/2004] [Indexed: 11/29/2022]
Abstract
Several reports have indicated that combinatorial regimens with DNA and protein vaccines can elicit both strong immune responses, to circumvent the limits of each vaccine. Surprisingly little was known on HBV vaccine. Here, we investigated the immunization effects of several regimens in BALB/c mice. The level of total antibody and isotypes of IgG were determined by ELISA. Cellular immune responses were assayed by measuring the production of cytokines and CTL activity after re-stimulation for 7 days in vitro with tumor cells CT26/S stably expressing HBsAg. The efficacy of immunoprotection against the challenge of transplanted CT26/S was also examined. The regimen involving twice priming pVAX(S) encoding HBsAg and once recombinant HBsAg protein (rHBsAg) boosting, induced strong and homogenous antibody responses. This regimen induced significant stronger responses of interleukin-12 and gamma interferon (IFN-gamma) in splenocytes, and elicited stronger CD8+ CTL responses and greater immunopretectional efficacy than those elicited by immunization with rHBsAg or pVAX(S) alone. Our regimen may thus provide a strategy for developing an improved immunization against HBV and many other pathogens.
Collapse
MESH Headings
- Adjuvants, Immunologic/genetics
- Adjuvants, Immunologic/pharmacology
- Adjuvants, Immunologic/therapeutic use
- Animals
- Antibody Formation/genetics
- Antibody Formation/immunology
- COS Cells
- Chlorocebus aethiops
- DNA, Viral/immunology
- Hepatitis B/immunology
- Hepatitis B/prevention & control
- Hepatitis B Surface Antigens/biosynthesis
- Hepatitis B Surface Antigens/genetics
- Hepatitis B Surface Antigens/immunology
- Hepatitis B Vaccines/immunology
- Hepatitis B Vaccines/pharmacology
- Hepatitis B Vaccines/therapeutic use
- Humans
- Immunity, Cellular/genetics
- Immunity, Cellular/immunology
- Mice
- Mice, Inbred BALB C
- Transfection
- Vaccines, Combined/immunology
- Vaccines, Combined/pharmacology
- Vaccines, Combined/therapeutic use
- Viral Proteins/genetics
- Viral Proteins/immunology
Collapse
Affiliation(s)
- He Xiao-wen
- Department of Medical Genetics, Second Military Medical University, Yangpu district, 200433 Shanghai, China.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Sunbul M, Leblebicioglu H. Distribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkey. World J Gastroenterol 2005; 11:1976-80. [PMID: 15800989 PMCID: PMC4305720 DOI: 10.3748/wjg.v11.i13.1976] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: Hepatitis B virus (HBV) strains isolated worldwide has been classified into eight genomic groups deduced from genome comparisons and designated as genotypes A to H. We aimed to investigate prevalence of HBV genotypes and subtypes in Turkey.
METHODS: A total of 88 chronic hepatitis B (CHB) patients from 15 hospitals throughout the country were included. Patients who were HBsAg positive in serum at least for 6 mo, who had HBV-DNA in serum and elevation of ALT levels more than two times upper limit of normal, and who had percutaneous liver biopsy within 6 mo were included. Genotyping of HBV was done by restriction fragment length polymorphism (RFLP). The patients received subcutaneous 9 MU interferon-α 2a thrice a week for a period of 6 mo.
RESULTS: Genotype D was detected in 78 of 88 (88.7%) patients, however, genotyping failed in two patients (2.3%), while no product was obtained in eight (9.0%) patients. Regarding subtypes, D2 was more prevalent (67 patients between 78% and 85.9%) followed by subtype D2+deletion (seven patients of 78 or 8.9%), subtype D1 (three patients of 78% or 3.9%) and subtype D3 (one patient of 78% or 1.3%). Thirty-three patients (37.5%) were HBeAg positive compared to 55 (62.5%) anti-HBe positive patients. The endpoint for the viral response of HBeAg positive patients was 27.2%, while it was found 52.7% in HBeAg negative patients (P<0.05). Long-term persistent viral response was 29.5% for all patients.
CONCLUSION: This multi-center study indicates that the predominant genotype with CHB patients in Turkey like in other Mediterranean countries is genotype D.
Collapse
Affiliation(s)
- Mustafa Sunbul
- Department of Infectious Diseases and Clinical Microbiology, Ondokuz Mayis University, Medical School, Samsun, Turkey.
| | | |
Collapse
|
9
|
He XW, Wang F, Jiang L, Li J, Liu SK, Xiao ZY, Jin XQ, Zhang YN, He Y, Li K, Guo YJ, Sun SH. Induction of mucosal and systemic immune response by single-dose oral immunization with biodegradable microparticles containing DNA encoding HBsAg. J Gen Virol 2005; 86:601-610. [PMID: 15722520 DOI: 10.1099/vir.0.80575-0] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
The purpose of this work was to assess the ability of plasmid DNA encoding hepatitis B virus (HBV) HBsAg encapsulated in poly(dl-lactide-co-glycolic acid) (PLGA) microparticles to induce local and systemic HBsAg-specific immunity following a single dose of oral immunization. RT-PCR analysis demonstrated prolonged transcription of plasmid DNA, consistent with the sustained expression and presentation of target antigen observed by confocal laser scanning microscopy, in gut-associated lymphocyte tissue (GALT) from mice immunized orally with plasmid DNA encapsulated into PLGA microparticles. Oral administration of PLGA-DNA microparticles induced a long-lasting and stable antigen-specific antibody response, both serum total antibody and intestinal IgA, in BALB/c mice. Mice immunized orally exhibited antigen-specific gamma interferon production and cytotoxic T lymphocyte responses in spleen and GALT after restimulation in vitro with HBsAg or tumour cells stably expressing HBsAg. In contrast, naked DNA vaccines given by intramuscular injection induced only systemic cellular and humoral responses to HBsAg, which were much lower than the responses elicited by oral DNA encapsulated in PLGA microparticles at equivalent doses. The results are encouraging with regard to obtaining good compliance and vaccination coverage with candidate plasmid DNA vaccines, especially in developing countries.
Collapse
Affiliation(s)
- Xiao-Wen He
- Department of Medical Genetics, The Second Military Medical University, No. 800 Xiangyin Road, Yangpu District, 200433 Shanghai, China
| | - Fang Wang
- Department of Medical Genetics, The Second Military Medical University, No. 800 Xiangyin Road, Yangpu District, 200433 Shanghai, China
| | - Lei Jiang
- Department of Medical Genetics, The Second Military Medical University, No. 800 Xiangyin Road, Yangpu District, 200433 Shanghai, China
| | - Jun Li
- Center of New Drug Research, The Naval Medical Research Institution, 200433 Shanghai, China
| | - Shan-Kui Liu
- School of Pharmaceutical Sciences, The Second Military Medical University, 200433 Shanghai, China
| | - Zhen-Yu Xiao
- School of Pharmaceutical Sciences, The Second Military Medical University, 200433 Shanghai, China
| | - Xiao-Qin Jin
- Center of New Drug Research, The Naval Medical Research Institution, 200433 Shanghai, China
| | - Ya-Nan Zhang
- Department of Medical Genetics, The Second Military Medical University, No. 800 Xiangyin Road, Yangpu District, 200433 Shanghai, China
| | - Ying He
- Department of Medical Genetics, The Second Military Medical University, No. 800 Xiangyin Road, Yangpu District, 200433 Shanghai, China
| | - Kai Li
- Department of Medical Genetics, The Second Military Medical University, No. 800 Xiangyin Road, Yangpu District, 200433 Shanghai, China
| | - Ying-Jun Guo
- Department of Medical Genetics, The Second Military Medical University, No. 800 Xiangyin Road, Yangpu District, 200433 Shanghai, China
| | - Shu-Han Sun
- Department of Medical Genetics, The Second Military Medical University, No. 800 Xiangyin Road, Yangpu District, 200433 Shanghai, China
| |
Collapse
|